Published in J Infect Dis on February 17, 2004
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
Endogenous CD4(+) CD25(+) regulatory T cells have a limited role in the control of Trypanosoma cruzi infection in mice. Infect Immun (2006) 1.25
Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection. J Exp Med (2007) 1.21
Development of a system to study CD4+-T-cell responses to transgenic ovalbumin-expressing Toxoplasma gondii during toxoplasmosis. Infect Immun (2004) 1.21
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Current concepts in immunoregulation and pathology of human Chagas disease. Curr Opin Infect Dis (2008) 1.17
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz (2009) 1.11
Regulatory T cells phenotype in different clinical forms of Chagas' disease. PLoS Negl Trop Dis (2011) 1.10
Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis (2011) 1.10
CD8+ T-cells expressing interferon gamma or perforin play antagonistic roles in heart injury in experimental Trypanosoma cruzi-elicited cardiomyopathy. PLoS Pathog (2012) 1.08
Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses. PLoS Pathog (2007) 1.07
Macrophage migration inhibitory factor contributes to host defense against acute Trypanosoma cruzi infection. Infect Immun (2006) 1.05
Oral vaccination with Salmonella enterica as a cruzipain-DNA delivery system confers protective immunity against Trypanosoma cruzi. Infect Immun (2007) 1.05
Regulation of CD8+ T cell responses to infection with parasitic protozoa. Exp Parasitol (2010) 1.04
Deficient regulatory T cell activity and low frequency of IL-17-producing T cells correlate with the extent of cardiomyopathy in human Chagas' disease. PLoS Negl Trop Dis (2012) 1.03
Impairment of T cell function in parasitic infections. PLoS Negl Trop Dis (2014) 1.01
Profile of central and effector memory T cells in the progression of chronic human chagas disease. PLoS Negl Trop Dis (2009) 0.96
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Analysis of the dynamics of infiltrating CD4(+) T cell subsets in the heart during experimental Trypanosoma cruzi infection. PLoS One (2013) 0.92
The liver plays a major role in clearance and destruction of blood trypomastigotes in Trypanosoma cruzi chronically infected mice. PLoS Negl Trop Dis (2010) 0.91
Chagas' disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med (2010) 0.91
Immunoregulatory networks in human Chagas disease. Parasite Immunol (2014) 0.90
Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study. J Antimicrob Chemother (2012) 0.89
Polyfunctional T cell responses in children in early stages of chronic Trypanosoma cruzi infection contrast with monofunctional responses of long-term infected adults. PLoS Negl Trop Dis (2013) 0.87
Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect (2010) 0.85
Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children. Am J Trop Med Hyg (2010) 0.85
Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi. PLoS One (2013) 0.84
Perforin-expressing cytotoxic cells contribute to chronic cardiomyopathy in Trypanosoma cruzi infection. Int J Exp Pathol (2009) 0.84
Blood leukocytes from benznidazole-treated indeterminate chagas disease patients display an overall type-1-modulated cytokine profile upon short-term in vitro stimulation with Trypanosoma cruzi antigens. BMC Infect Dis (2012) 0.84
Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives. Mem Inst Oswaldo Cruz (2015) 0.82
An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8(+) T cell epitopes. Hum Vaccin Immunother (2015) 0.82
T lymphocytes from chagasic patients are activated but lack proliferative capacity and down-regulate CD28 and CD3ζ. PLoS Negl Trop Dis (2013) 0.81
Low frequency of circulating CD8+ T stem cell memory cells in chronic chagasic patients with severe forms of the disease. PLoS Negl Trop Dis (2015) 0.81
Perturbed T cell IL-7 receptor signaling in chronic Chagas disease. J Immunol (2015) 0.80
CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development? Mediators Inflamm (2014) 0.80
Different infective forms trigger distinct immune response in experimental Chagas disease. PLoS One (2012) 0.80
The heart of the matter: protection of the myocardium from T cells. J Autoimmun (2013) 0.79
A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi. PLoS Pathog (2015) 0.79
Depletion of regulatory T cells decreases cardiac parasitosis and inflammation in experimental Chagas disease. Parasitol Res (2015) 0.79
Protective human leucocyte antigen haplotype, HLA-DRB1*01-B*14, against chronic Chagas disease in Bolivia. PLoS Negl Trop Dis (2012) 0.79
Allopurinol reduces antigen-specific and polyclonal activation of human T cells. Front Immunol (2012) 0.77
Presence of antigen-experienced T cells with low grade of differentiation and proliferative potential in chronic Chagas disease myocarditis. PLoS Negl Trop Dis (2014) 0.77
Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease. Mem Inst Oswaldo Cruz (2015) 0.77
Chagasic patients are able to respond against a viral antigen from influenza virus. BMC Infect Dis (2012) 0.76
Trypanosoma cruzi Causes Paralyzing Systemic Necrotizing Vasculitis Driven by Pathogen-Specific Type I Immunity in Mice. Infect Immun (2016) 0.76
CD8(+) T Cell Responses to Plasmodium and Intracellular Parasites. Curr Immunol Rev (2013) 0.76
Circulating serum markers and QRS scar score in Chagas cardiomyopathy. Am J Trop Med Hyg (2014) 0.76
A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease. Hum Vaccin Immunother (2016) 0.76
Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity. PLoS Pathog (2016) 0.75
Treatment Success in Trypanosoma cruzi Infection Is Predicted by Early Changes in Serially Monitored Parasite-Specific T and B Cell Responses. PLoS Negl Trop Dis (2016) 0.75
The Aryl Hydrocarbon Receptor Modulates Production of Cytokines and Reactive Oxygen Species and Development of Myocarditis during Trypanosoma cruzi Infection. Infect Immun (2016) 0.75
Differential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients. PLoS One (2015) 0.75
Frequency of IFNγ-producing T cells correlates with seroreactivity and activated T cells during canine Trypanosoma cruzi infection. Vet Res (2014) 0.75
Regional variation in the correlation of antibody and T-cell responses to Trypanosoma cruzi. Am J Trop Med Hyg (2014) 0.75
Does cyclophosphamide play a protective role against neuronal loss in chronic T. cruzi infection? Dig Dis Sci (2008) 0.75
The Significance of Discordant Serology in Chagas Disease: Enhanced T-Cell Immunity to Trypanosoma cruzi in Serodiscordant Subjects. Front Immunol (2017) 0.75
Ebi3 Prevents Trypanosoma cruzi-Induced Myocarditis by Dampening IFN-γ-Driven Inflammation. Front Immunol (2017) 0.75
Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med (2006) 4.58
Serotype identification of group B streptococci by PCR and sequencing. J Clin Microbiol (2002) 2.86
A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results. Mol Cell Proteomics (2005) 2.52
MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine (2005) 2.20
Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat Med (2008) 2.04
Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther (2009) 1.99
CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog (2006) 1.93
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine (2009) 1.88
Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol (2003) 1.88
In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl Trop Dis (2010) 1.72
[Treatment of Chagas disease with benznidazole and thioctic acid]. Medicina (B Aires) (2004) 1.63
Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy. Clin Infect Dis (2009) 1.62
[Clinical predictors of chronic chagasic myocarditis progression]. Rev Esp Cardiol (2005) 1.60
Molecular profiles of group B streptococcal surface protein antigen genes: relationship to molecular serotypes. J Clin Microbiol (2002) 1.54
Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol (2005) 1.51
Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol (2006) 1.51
High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl Trop Dis (2008) 1.46
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Chromosome level assembly of the hybrid Trypanosoma cruzi genome. BMC Genomics (2009) 1.42
Potential new clinical therapies for Chagas disease. Expert Rev Clin Pharmacol (2014) 1.42
[Predictors of heart failure in chronic chagasic cardiomyopathy with asymptomatic left ventricular dysfunction]. Rev Esp Cardiol (2008) 1.42
CD8+ T cells in Trypanosoma cruzi infection. Curr Opin Immunol (2009) 1.36
Trypanosoma cruzi DNA in cardiac lesions of Argentinean patients with end-stage chronic chagas heart disease. Am J Trop Med Hyg (2004) 1.35
The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics (2009) 1.33
Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol (2005) 1.33
New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J Infect Dis (2013) 1.23
HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells in chronic Chagas disease. PLoS Negl Trop Dis (2008) 1.19
Towards a genotyping system for Streptococcus agalactiae (group B streptococcus): use of mobile genetic elements in Australasian invasive isolates. J Med Microbiol (2003) 1.18
Insufficient TLR activation contributes to the slow development of CD8+ T cell responses in Trypanosoma cruzi infection. J Immunol (2009) 1.17
Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J Immunol (2009) 1.12
Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl Trop Dis (2011) 1.10
The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic. N Z Med J (2004) 1.10
Widespread, focal copy number variations (CNV) and whole chromosome aneuploidies in Trypanosoma cruzi strains revealed by array comparative genomic hybridization. BMC Genomics (2011) 1.09
From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine (2005) 1.07
Evaluation of high efficiency gene knockout strategies for Trypanosoma cruzi. BMC Microbiol (2009) 1.07
Eliminating Chagas disease: challenges and a roadmap. BMJ (2009) 1.06
Stable CD8+ T cell memory during persistent Trypanosoma cruzi infection. J Immunol (2008) 1.05
A systematic review of high quality diagnostic tests for Chagas disease. PLoS Negl Trop Dis (2012) 1.05
Regulation of surface coat exchange by differentiating African trypanosomes. Mol Biochem Parasitol (2006) 1.04
Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh. Am J Trop Med Hyg (2013) 1.02
Cutting edge: dysfunctional CD8+ T cells reside in nonlymphoid tissues during chronic Trypanosoma cruzi infection. J Immunol (2003) 1.02
CD8+ T cells specific for immunodominant trans-sialidase epitopes contribute to control of Trypanosoma cruzi infection but are not required for resistance. J Immunol (2010) 1.02
Methodological advances in drug discovery for Chagas disease. Expert Opin Drug Discov (2011) 0.98
Microarray profiling of gene expression during trypomastigote to amastigote transition in Trypanosoma cruzi. Mol Biochem Parasitol (2003) 0.98
Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine (2003) 0.96
Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease. PLoS One (2012) 0.95
Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challenge. Infect Immun (2011) 0.94
New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J (2007) 0.94
Intracellular growth of Trypanosoma cruzi in cardiac myocytes is inhibited by cytokine-induced nitric oxide release. Infect Immun (2004) 0.93
Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N Z Med J (2004) 0.93
TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection. Eur J Immunol (2007) 0.91
A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi. Genome Biol (2007) 0.90
Limited role for CD4+ T-cell help in the initial priming of Trypanosoma cruzi-specific CD8+ T cells. Infect Immun (2006) 0.90
Report of the 2nd Chagas Drug Discovery Consortium meeting, held on 3 November 2010; Atlanta GA, USA. Expert Opin Drug Discov (2011) 0.90
Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library. Vaccine (2009) 0.89
Cavia porcellus as a model for experimental infection by Trypanosoma cruzi. Am J Pathol (2011) 0.89
Clinical characteristics and outcome of 107 adult patients with chronic Chagas disease and parasitological cure criteria. Trans R Soc Trop Med Hyg (2013) 0.89
Inducible nitric oxide synthase is not essential for control of Trypanosoma cruzi infection in mice. Infect Immun (2004) 0.89
Evidence for the role of vacuolar soluble pyrophosphatase and inorganic polyphosphate in Trypanosoma cruzi persistence. Mol Microbiol (2013) 0.89
Involvement of streptococcal mitogenic exotoxin Z in streptococcal toxic shock syndrome. J Clin Microbiol (2005) 0.88
Perpetual expression of PAMPs necessary for optimal immune control and clearance of a persistent pathogen. Nat Commun (2013) 0.88
TcruziDB: an integrated Trypanosoma cruzi genome resource. Nucleic Acids Res (2004) 0.88
Cardiac myocyte hypertrophy and proliferating cell nuclear antigen expression in Wistar rats infected with Trypanosoma cruzi. J Parasitol (2002) 0.87
Chagas' disease: study of congenital transmission in cases of acute maternal infection. Rev Soc Bras Med Trop (2005) 0.87
Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol (2007) 0.86
Granulocyte colony-stimulating factor partially repairs the damage provoked by Trypanosoma cruzi in murine myocardium. Int J Cardiol (2013) 0.86
Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect (2010) 0.85
Assessment of CD8(+) T cell differentiation in Trypanosoma cruzi-infected children. Am J Trop Med Hyg (2010) 0.85
Patterns of cytokines and soluble cellular receptors in the sera of children with acute chagas' disease. Clin Diagn Lab Immunol (2002) 0.84
Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation. J Med Chem (2005) 0.83
Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child (2011) 0.83
Generation of Trypanosoma cruzi-specific CD8+ T-cell immunity is unaffected by the absence of type I interferon signaling. Infect Immun (2010) 0.83
Trypanosoma cruzi: biological characterization of a isolate from an endemic area and its susceptibility to conventional drugs. Exp Parasitol (2010) 0.82
Multidimensional analysis of the insoluble sub-proteome of Oceanobacillus iheyensis HTE831, an alkaliphilic and halotolerant deep-sea bacterium isolated from the Iheya ridge. Proteomics (2007) 0.82
Timing of expression of inflammatory mediators in skeletal muscles from mice acutely infected with the RA strain of Trypanosoma cruzi. Pathobiology (2009) 0.81
Multidimensional proteomic analysis of the soluble subproteome of the emerging nosocomial pathogen Ochrobactrum anthropi. J Proteome Res (2006) 0.80
Transgenic parasites accelerate drug discovery. Trends Parasitol (2012) 0.80
Knockout of the dhfr-ts gene in Trypanosoma cruzi generates attenuated parasites able to confer protection against a virulent challenge. PLoS Negl Trop Dis (2011) 0.80
XV Lancefield Symposium on Streptococci and Streptococcal Diseases. Indian J Med Res (2004) 0.78
Elevated serum levels of macrophage migration inhibitory factor are associated with progressive chronic cardiomyopathy in patients with Chagas disease. PLoS One (2013) 0.78
A combined shotgun and multidimensional proteomic analysis of the insoluble subproteome of the obligate thermophile, Geobacillus thermoleovorans T80. J Proteome Res (2006) 0.78
The beneficial impact of Hib vaccine on disease rates in New Zealand children. N Z Med J (2002) 0.77
Natriuretic peptides as prognostic and diagnostic markers in Chagas' disease. Regul Pept (2005) 0.77
Allopurinol reduces antigen-specific and polyclonal activation of human T cells. Front Immunol (2012) 0.77
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines. Bioorg Med Chem (2010) 0.77